Cipla wins cancer drug patent case over Tarceva

10 Sep 2012 Evaluate

Pharma major, Cipla has won a landmark patent case against Swiss drug maker F Hoffmann-La Roche in the Delhi High Court on September 7, 2012 over the Indian company’s generic copy of lung cancer drug Tarceva after a four-year court battle.

As per the Delhi High Court, Cipla's drug - Erlocip did not violate the Roche patent on its anti-lung cancer medication Tarceva due to its different molecular make-up. Justice Manmohan Singh observed in his 280-page judgment that it had been scientifically proven that Cipla’s generic version was a polymorph B variant of Roche’s patented drug and that it didn’t actually infringe any patent in India.

Cipla Share Price

1326.30 0.20 (0.02%)
24-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1730.55
Dr. Reddys Lab 1299.40
Cipla 1326.30
Zydus Lifesciences 904.35
Lupin 2251.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×